跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SOLIQUA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SOLIQUA
Authorized
STANDARD
SOLIQUA
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8678db21badaa00f
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
8678db21badaa00f
Drug Approval Canada Name
SOLIQUA
Product Name
SOLIQUA
Status
Marketed
Status Date
2018-09-12
Original Market Date
2018-09-12
Din
02478293
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
68:20.08
Atc Original
A10AE54 INSULIN GLARGINE AND LIXISENATIDE
Atc Name
a 10 ae 54
Aig Number
0260350001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
LIXISENATIDE
33 MCG / ML
INSULIN GLARGINE
100 UNIT / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8678db21badaa00f
Type
Standard
Back to Health Canada Approvals